Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1978 Sep;21(3):905–913. doi: 10.1128/iai.21.3.905-913.1978

Role of Nonagglutinating Antibody in the Protracted Immunity of Vaccinated Mice to Pseudomonas aeruginosa Infection

M R Moody 1, R W I Kessel 2, V M Young 1, P Fiset 2
PMCID: PMC422082  PMID: 101467

Abstract

Effective immunization against infection with Pseudomonas aeruginosa is difficult to evaluate because agglutinin levels decline rapidly. Because fractionation of hyperimmune sera often yields more specific antibody than can be accounted for by direct agglutination tests, an immunoglobulin-specific assay based on antiglobulin augmentation was used to characterize antibody responses of C3H/HeJ mice vaccinated with P. aeruginosa type 2 lipopolysaccharide. Nonagglutinating antibodies, initially detected at 2 weeks post-primary vaccination, were predominantly immunoglobulin G after 5 weeks, and they remained elevated at levels usually 32-fold higher than the direct titer throughout the 4-month study period. The sequential production of immunoglobulin M, then immunoglobulin G, followed that found in orthodox immunological responses. Sera that contained nonagglutinating antibodies but not direct agglutinins (14 to 16 weeks) enhanced phagocytosis of P. aeruginosa type 2 by macrophages from unimmunized mice and passively immunized mice against lethal challenge doses; bactericidal activity of these sera was not demonstrated in the presence or absence of complement. When challenged with 1, 10, and 100 50% lethal doses at 16 weeks, survival rates of actively immunized mice were significantly higher than those of unvaccinated mice (P < 0.001). Thus, at a time when no direct agglutinins were detectable, the augmented system detected nonagglutinating antibodies that could confer protracted resistance in vaccinated mice to pseudomonas infection.

Full text

PDF
913

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander J. W., Fisher M. W., MacMillan B. G., Altemeier W. A. Prevention of invasive pseudomonas infection in burns with a new vaccine. Arch Surg. 1969 Aug;99(2):249–256. doi: 10.1001/archsurg.1969.01340140121018. [DOI] [PubMed] [Google Scholar]
  2. Alexander J. W., Fisher M. W., MacMillan B. G. Immunological control of Pseudomonas infection in burn patients: a clinical evaluation. Arch Surg. 1971 Jan;102(1):31–35. doi: 10.1001/archsurg.1971.01350010033008. [DOI] [PubMed] [Google Scholar]
  3. Alexander J. W. Serum and leukocyte lysosomal enzymes. Derangements following severe thermal injury. Arch Surg. 1967 Sep;95(3):482–491. doi: 10.1001/archsurg.1967.01330150158020. [DOI] [PubMed] [Google Scholar]
  4. Anderson R. J., Schafer L. A., Olin D. B., Eickhoff T. C. Septicemia in renal transplant recipients. Arch Surg. 1973 May;106(5):692–694. doi: 10.1001/archsurg.1973.01350170058014. [DOI] [PubMed] [Google Scholar]
  5. Bjornson A. B., Michael J. G. Biological Activities of Rabbit Immunoglobulin M and Immunoglobulin G Antibodies to Pseudomonas aeruginosa. Infect Immun. 1970 Oct;2(4):453–461. doi: 10.1128/iai.2.4.453-461.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bjornson A. B., Michael J. G. Contribution of humoral and cellular factors to the resistance to experimental infection by Pseudomonas aeruginosa in mice. I. Interaction between immunoglobulins, heat-labile serum factors, and phagocytic cells in the killing of bacteria. Infect Immun. 1971 Oct;4(4):462–467. doi: 10.1128/iai.4.4.462-467.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bjornson A. B., Michael J. G. Contribution of humoral and cellular factors to the resistance to experimental infection by Pseudomonas aeruginosa in mice. II. Opsonic, agglutinative, and protective capacities of immunoglobulin G anti-Pseudomonas antibodies. Infect Immun. 1972 May;5(5):775–782. doi: 10.1128/iai.5.5.775-782.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bryant R. E., Hood A. F., Hood C. E., Koenig M. G. Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med. 1971 Jan;127(1):120–128. [PubMed] [Google Scholar]
  9. Crowder J. G., Fisher M. W., White A. Type-specific immunity in pseudomonas diseases. J Lab Clin Med. 1972 Jan;79(1):47–54. [PubMed] [Google Scholar]
  10. Davis S. D. Efficacy of modified human immune serum globulin in the treatment of experimental murine infections with seven immunotypes of Pseudomonas aeruginosa. J Infect Dis. 1975 Jun;131(6):717–721. doi: 10.1093/infdis/131.6.717. [DOI] [PubMed] [Google Scholar]
  11. Feller I., Pierson C. Pseudomonas vaccine and hyperimmune plasma for burned patients. Arch Surg. 1968 Aug;97(2):225–229. doi: 10.1001/archsurg.1968.01340020089010. [DOI] [PubMed] [Google Scholar]
  12. Fisher M. W., Devlin H. B., Gnabasik F. J. New immunotype schema for Pseudomonas aeruginosa based on protective antigens. J Bacteriol. 1969 May;98(2):835–836. doi: 10.1128/jb.98.2.835-836.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fishman L. S., Armstrong D. Pseudomonas aeruginosa bacteremia in patients with neoplastic disease. Cancer. 1972 Sep;30(3):764–773. doi: 10.1002/1097-0142(197209)30:3<764::aid-cncr2820300326>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  14. Freid M. A., Vosti K. L. The importance of underlying disease in patients with gram-negative bacteremia. Arch Intern Med. 1968 May;121(5):418–423. [PubMed] [Google Scholar]
  15. Haghbin M., Armstrong D., Murphy M. L. Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia. Cancer. 1973 Oct;32(4):761–766. doi: 10.1002/1097-0142(197310)32:4<761::aid-cncr2820320405>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  16. Hanessian S., Regan W., Watson D., Haskell T. H. Isolation and characterization of antigenic components of a new heptavalent Pseudomonas vaccine. Nat New Biol. 1971 Feb 17;229(7):209–210. doi: 10.1038/newbio229209a0. [DOI] [PubMed] [Google Scholar]
  17. Harvath L., Andersen B. R. Evaluation of type-specific and non-type-specific pseudomonas vaccine for treatment of pseudomonas sepsis during granulocytopenia. Infect Immun. 1976 Apr;13(4):1139–1143. doi: 10.1128/iai.13.4.1139-1143.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Homma J. Y., Shionoya H., Yamada H., Kawabe Y. Production of antibody against Pseudomonas aeruginosa and its serological typing. Jpn J Exp Med. 1971 Feb;41(1):89–94. [PubMed] [Google Scholar]
  19. Jones R. J., Hall M., Ricketts C. R. Passive protective properties of serum fractions from mice inoculated with an anti-pseudomonas vaccine. Immunology. 1972 Dec;23(6):889–895. [PMC free article] [PubMed] [Google Scholar]
  20. Jones R. J., Roe E. A. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine. Br J Exp Pathol. 1975 Feb;56(1):34–43. [PMC free article] [PubMed] [Google Scholar]
  21. Pennington J. E. Preliminary investigations of Pseudomonas aeruginosa vaccine in patients with leukemia and cystic fibrosis. J Infect Dis. 1974 Nov;130 (Suppl)(0):S159–S162. doi: 10.1093/infdis/130.supplement.s159. [DOI] [PubMed] [Google Scholar]
  22. Pennington J. E., Reynolds H. Y., Wood R. E., Robinson R. A., Levine A. S. Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis. Am J Med. 1975 May;58(5):629–636. doi: 10.1016/0002-9343(75)90498-2. [DOI] [PubMed] [Google Scholar]
  23. Roe E. A., Jones R. J. Intracellular killing of different strains of Pseudomonas aeruginosa by human leucocytes. Br J Exp Pathol. 1974 Aug;55(4):336–343. [PMC free article] [PubMed] [Google Scholar]
  24. Whitecar J. P., Jr, Luna M., Bodey G. P. Pseudomonas bacteremia in patients with malignant diseases. Am J Med Sci. 1970 Oct;60(4):216–223. doi: 10.1097/00000441-197010000-00003. [DOI] [PubMed] [Google Scholar]
  25. Young L. S. Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides. J Infect Dis. 1972 Sep;126(3):277–287. doi: 10.1093/infdis/126.3.277. [DOI] [PubMed] [Google Scholar]
  26. Young L. S., Meyer R. D., Armstrong D. Pseudomonas aeruginosa vaccine in cancer patients. Ann Intern Med. 1973 Oct;79(4):518–527. doi: 10.7326/0003-4819-79-4-518. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES